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Abstract
© 2018 Media Sphera Publishing Group. All rights reserved. Aim: to assess the effectiveness of
mebeverine  200 mg BID in  patients  with  post-cholecystectomy gastrointestinal  spasm not
requiring surgical treatment. Materials and methods. 218 patients were included in 16 clinical
centers in 14 cities in Russia. All patients had post-cholecystectomy gastrointestinal spasms, not
requiring  surgical  treatment  and  received  mebeverine  (Duspatalin®)  200  mg  BID.  The
observational assessment period lasted from the moment of their inclusion into the study up to
6 weeks post inlusion. The therapy results were evaluated using visual analog scales (GPA and
11-point numeric rating scale) by patient self-assessment of the dynamics of spasm/discomfort
and other postcholecystectomic gastrointestinal symptoms after 2 and 6 weeks of treatment.
Gastrointestinal Quality of Life Index (GIQLI) was used to assess patient quality of life. Results
and discussion. All 218 patients completed the 2-week mebeverine treatment course, 101 of
them finished the 6-week course ("prolonged population"). Significant positive changes in the
relief of abdominal pain and dyspepsia were noted as well as normalization of stool frequency
and consistency. A more marked change in values was observed during prolonged (up to 6
weeks) therapy. Both 2-week and 6-week mebeverine courses led to a normalization of patient
quality of life. After 6 week therapy, an effect of mebeverine on the quality of life 91% of
patients was observed comparable to cholecystectomy itself, speficially related to the quality of
life subscore 'symptoms'. Conclusion. The results of our study demonstrate that mebeverine
(Duspatalin®) therapy leads to an effective elimination of clinical symptoms associated with
post-cholecystectomy GI-spasm disorders,  like abdominal  pain,  symptoms of dyspepsia and
stooldisorders. A more marked change in values was observed during prolonged (up to 6 weeks)
therapy.
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